RT Book, Section
A1 Sohda, Makoto
A1 Miyazaki, Tatsuya
A1 Yokobori, Takehiko
A1 Sakai, Makoto
A1 Kuwano, Hiroyuki
A2 Morita, Shane Y.
A2 Balch, Charles M.
A2 Klimberg, V. Suzanne
A2 Pawlik, Timothy M.
A2 Posner, Mitchell C.
A2 Tanabe, Kenneth K.
SR Print(0)
ID 1145761234
T1 Multimodality Therapy for Esophageal Cancer: Eastern Experience
T2 Textbook of Complex General Surgical Oncology
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9780071793315
LK accesssurgery.mhmedical.com/content.aspx?aid=1145761234
RD 2024/04/23
AB The  majority  of  esophageal  carcinomas  are  represented  by  two  histologies:  squamous  cell  carcinoma  and  adenocarcinoma.  Esophageal  squamous  cell  carcinoma  (ESCC)  is  the  predominant  histological  type  in  Asia.  Although  treatment  strategies  differ  slightly  between  Western  and  Asian  countries,  surgery  traditionally  remains  the  standard  therapy  for  esophageal  cancer.  However,  survival  after  surgery  alone  remains  poor  because  of  the  high  rates  of  local  and  systemic  failure.  Thus,  multimodality  therapies  using  various  combinations  of  all  modalities  including  surgery,  radiotherapy,  chemotherapy,  and  chemoradiotherapy  (CRT)  have  been  investigated.  In  this  chapter,  we  described  recent  issues  regarding  multimodality  therapy  for  esophageal  cancer  in  Eastern  countries.